HSPA5 and glioblastoma: In vivo, we found that systemic combination of TMZ with a single intravenous dose of RGD4C/AAVP‐Grp78‐HSVtk and GCV yielded synergistic and more pronounced anti‐tumor effect than gene therapy or chemotherapy alone, both against orthotopic U87‐derived xenografts and human primary GBM.